Suzanne L. Wolden, MD, FACR
Director, Pediatric Radiation Oncology
Pediatric Radiation Oncology; Intensity Modulated Radiation Therapy; Image-Guided Radiation Therapy; Intra-Operative Radiation Therapy; Proton Therapy
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Wolden accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, University of California San Francisco
Radiation Oncology - Stanford University Medical Center
Since 1998, I have been the Director of Pediatric Radiation Oncology on the MSK Kids team who cares for children and young adults with cancer. I am a member of the pediatric, ophthalmic, and bone marrow transplant disease management teams at MSK and work very closely with surgeons and medical oncologists in these specialties.
I have extensive experience treating rare diseases in young people such as sarcomas, brain tumors, neuroblastoma, Wilms’ tumor, lymphoma, and leukemia. Radiation therapy is an extremely powerful tool for these tumors, but young patients are especially sensitive to long-term side effects. I therefore approach each patient as a unique individual, carefully designing a highly customized radiation therapy plan to maximize the benefits of treatment while minimizing side effects. I am a leader in the use of targeted approaches such as proton therapy, intensity-modulated radiation therapy, image-guided radiation therapy, and intra-operative radiation therapy for pediatric cancers.
In the Brain Tumor Center, I treat all children and teenagers with cancers of the brain and spinal cord (central nervous system). My clinical research has led to changes in our approach to the treatment of tumors such as medulloblastoma and central nervous system germ cell tumors. We are very mindful of patients’ long-term quality of life and seek to maintain the highest possible survival rates while minimizing the risk of potential long-term treatment complications.
I am involved in numerous clinical trials and oversee large international studies for the Children’s Oncology Group in the areas of soft-tissue sarcoma and Hodgkin lymphoma. I am involved with research on the late effects of radiation therapy through my collaboration with the Childhood Cancer Survivor Study.
I find it very rewarding to work with a team that couples extraordinary experience with compassion to care for patients with cancer. I am optimistic that our ongoing research will lead to higher cure rates as well as improved long-term quality of life for our patients.
I find it very rewarding to work with a team that couples extraordinary experience with compassion to care for patients with cancer.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2007-2020)
- Clinical Trials Investigated by Dr. Wolden
- A Study Assessing Lower-Dose Radiation Therapy for High-Risk Neuroblastoma
- Clinical Trials Co-Investigated by Dr. Wolden
- A Phase I/II Study of Selinexor and Radiation Therapy for Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
- A Phase II Study of 131I-Omburtamab plus Radiotherapy in People with Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
- A Phase II Study of a Modified Dose of rATG in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
- A Phase II Study of Chemotherapy Followed by Radiation Therapy for Children and Young Adults with Localized Non-Germinomatous Germ Cell Tumors of the Brain or Spinal Cord
- A Phase II Study of Combination Chemotherapy, Surgery, and Radiation Therapy for Patients with High-Risk Wilms' Tumors
- A Phase II Study of Reduced Therapy for Patients Newly Diagnosed with Average-Risk WNT-Driven Medulloblastoma
- A Phase III Study Comparing Standard Chemotherapy to Treatment with CPX-351 and/or Gilteritinib for Children Newly Diagnosed with Acute Myeloid Leukemia
- A Phase III Study of Different Treatments for People Newly Diagnosed with Very Low-Risk and Low-Risk Rhabdomyosarcoma
- A Phase III Study of Standard Chemotherapy with Either Nivolumab Immunotherapy or Brentuximab Vedotin to Treat Newly Diagnosed Advanced Classical Hodgkin Lymphoma
- A Phase III Study to Compare Early Use of Vinorelbine and Maintenance Therapy for People with High-Risk Rhabdomyosarcoma
- A Study of How Proton Beam Radiotherapy Affects Brain Function and Quality of Life in Children and Young Adults Undergoing Treatment for a Brain Tumor
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Wolden’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Suzanne L. Wolden discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.